FN2 Earnings Intelligence
Eli Lilly and Company ratios (quarterly)
Eli Lilly and Company (LLY) Ratios (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $3,093.3 | $3,375.9 | $9,791.9 | $5,282 | $8,950 | - | - |
| + Debt | $38,515.9 | $39,903.8 | $42,506.6 | $43,370 | $54,908 | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $12,728.5 | $15,557.7 | $17,600.8 | $19,799 | $22,974 | $22,193.1 | $23,176.9 |
| % Growth | - | - | - | - | - | 26.1% | - |
| Gross Profit | $10,504.3 | $13,109.9 | $14,592.5 | $16,222 | $19,706 | - | - |
| % Margin | 82.5% | 84.3% | 82.9% | 81.9% | 85.8% | - | - |
| EBITDA | - | - | - | - | - | - | - |
| % Margin | - | - | - | - | - | - | - |
| Net Income | $2,759.3 | $5,660.5 | $5,582.5 | $7,396 | $7,095 | - | - |
| % Margin | 21.7% | 36.4% | 31.7% | 37.4% | 30.9% | - | - |
| Diluted EPS | $3.06 | $6.29 | $6.21 | $8.26 | $7.94 | $9.85 | $9.96 |
| % Growth | - | - | - | - | - | 58.6% | - |
| Operating Cash Flow | $1,665.6 | - | - | $5,333 | - | - | - |
| CapEx | $1,509.5 | - | - | $2,326 | - | - | - |
| Free Cash Flow | $156.1 | - | - | $3,007 | - | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $12,728.5 | $15,557.7 | $17,600.8 | $19,799 | $22,974 | $22,193.1 | $23,176.9 |
| Gross Profit | $10,504.3 | $13,109.9 | $14,592.5 | $16,222 | $19,706 | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Net Income | $2,759.3 | $5,660.5 | $5,582.5 | $7,396 | $7,095 | - | - |
| Diluted EPS | $3.06 | $6.29 | $6.21 | $8.26 | $7.94 | $9.85 | $9.96 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $3,093.3 | $3,375.9 | $9,791.9 | $5,282 | $8,950 |
| Short-term Debt | $4,016.4 | $5,723.7 | $1,633 | $4,000 | $7,050 |
| Long-term Debt | $34,499.5 | $34,180.1 | $40,873.6 | $39,370 | $47,858 |
| Total Debt | $38,515.9 | $39,903.8 | $42,506.6 | $43,370 | $54,908 |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1,665.6 | - | - | $5,333 | - |
| Capital Expenditure | $1,509.5 | - | - | $2,326 | - |
| Free Cash Flow | $156.1 | - | - | $3,007 | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 82.5% | 84.3% | 82.9% | 81.9% | 85.8% |
| EBITDA Margin | - | - | - | - | - |
| Net Margin | 21.7% | 36.4% | 31.7% | 37.4% | 30.9% |
| FCF Margin | 1.2% | - | - | 15.2% | - |
| Diluted EPS Growth | - | - | - | - | - |
Get the LLY recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.